Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Joint Authors
Hogan, Eileen
Kane, Michael P.
Micale, Sara J.
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-10-03
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Liraglutide is a glucagon-like peptide 1 (GLP-1) analog indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults.
Liraglutide lowers blood glucose levels by stimulating insulin secretion and decreasing glucagon release in glucose-dependent manners, increases satiety, and delays gastric emptying.
Liraglutide, unlike metformin and insulin, is not approved for use in the pediatric population.
We report the successful off-label use of liraglutide in an obese, 16 year old Caucasian female with type 2 diabetes mellitus.
American Psychological Association (APA)
Micale, Sara J.& Kane, Michael P.& Hogan, Eileen. 2013. Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus. Case Reports in Pediatrics،Vol. 2013, no. 2013, pp.1-4.
https://search.emarefa.net/detail/BIM-491874
Modern Language Association (MLA)
Micale, Sara J.…[et al.]. Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus. Case Reports in Pediatrics No. 2013 (2013), pp.1-4.
https://search.emarefa.net/detail/BIM-491874
American Medical Association (AMA)
Micale, Sara J.& Kane, Michael P.& Hogan, Eileen. Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus. Case Reports in Pediatrics. 2013. Vol. 2013, no. 2013, pp.1-4.
https://search.emarefa.net/detail/BIM-491874
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-491874
